• Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines

    October 27, 2014   Guidelines provide evidence-based, consensus-driven recommendations for managing cancer. Biodesix Inc., a molecular diagnostics company dedicated to advancing precision medicine and improved patient care, today announced that its VeriStrat® blood-based prognostic and predictive proteomics test has been approved for inclusion in the National Comprehensive Cancer Network ... Read more
  • AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress

    September 29, 2014 AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO’s HGF inhibitory antibody, to epidermal growth factor ... Read more
  • Biodesix Receives Highmark Blue Cross Blue Shield Coverage for VeriStrat Test

    September 9, 2014 Lung cancer diagnostic deemed medically necessary to guide treatment decisions Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that its VeriStrat® test received a positive coverage decision from Highmark Inc., a Blue Cross Blue Shield (BCBS) affiliate organization and one of the largest insurance companies in the United States. Highmark announced ... Read more
  • Biodesix Announces Publication of Seminal PROSE Study in THE LANCET ONCOLOGY

    May 14, 2014 Study highlights VeriStrat®’s ability to predict differential treatment outcomes between erlotinib and chemotherapy for non-small cell lung cancer Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced the publication of results from the investigator-initiated study, “Randomised ... Read more
  • AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC

    April 10, 2014 Biodesix to Fund Proof of Concept Study  AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. This agreement and the clinical ... Read more
  • Biodesix Receives CE Mark for VeriStrat Specimen Collection and Shipping Kit

    March 3, 2014 Blood-based protein diagnostic predicts differential treatment outcomes for non-small cell lung cancer Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that it has obtained the CE Mark for its VeriStrat® specimen collection and shipping kit, ... Read more
  • Biodesix and Capital Royalty Close Financing Transaction

    February 12, 2014 Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed a structured debt financing with Capital Royalty Partners L.P.  The transaction provides Biodesix®with up to $20 million of capital. “Capital Royalty’s financing structure has been uniquely tailored to suit our capital needs, especially during ... Read more
  • Biodesix Adds to Series E Financing

    January 13, 2014 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company increased the size of its recent offering of series E preferred shares in a follow-on sale. In addition to the $8.3 million of series E shares sold a month ago, the company brought in ... Read more
  • Biodesix Closes Series E Financing

    December 3, 2013 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed an $8.3 million Series E preferred equity financing. New funds accounted for $4.3 million of the round and the remaining $4 million came from the conversion of a convertible note. Existing Biodesix shareholders ... Read more
  • Biodesix to Present at World CDx

    November 15, 2013 Session Examines Use of Proteomics and Mass Spec to Improve Biomarker Validation BOSTON AND BOULDER, Colo.– November 13, 2013 – Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Vice President of Business Development and Strategic Marketing, Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in ... Read more